Author

Eva Hellström-Lindberg

Karolinska University Hospital

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:protein structure prediction· 2 Approach:benchmark study· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Assay:long-read sequencing· 1

Frequent Co-Authors

Maria CreignouiD· 2 shared Seishi OgawaiD· 2 shared Yasuhito NannyaiD· 2 shared Agnes J. VialeiD· 1 shared Akifumi Takaori‐KondoiD· 1 shared Alexandra Argyriou· 1 shared Alexandra G. SmithiD· 1 shared Andrea PellagattiiD· 1 shared

Activity by Year

2020-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Maria CreignouORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

RNA splicing factor mutations drive myeloid neoplasm oncogenesis through protein complex poisoning

Pedro Luís Moura, Rui Mamede Branca, Yaroslav Kaminskiy, Ioannis Siavelis, Kovi R Shrung, Sophia Hofmann, Christina Maria Perraki, Alexandra Argyriou, Sadaf Fazeli, Masahiro M Nakagawa, Teresa Mortera Blanco, Steffen Boettcher, Caroline Kubaczka, Thorsten M. Schlaeger, Maria Creignou, , Eva Hellström-Lindberg

This study identifies how RNA splicing factor mutations drive myeloid neoplasm by disrupting proteomic networks through mis-splicing, validated via single-cell transcriptomics and proteomics.

bioRxiv · Sep 30, 2026 · PreprintCancer Biology

Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, Yasuhito Nannya, Robert Paul Hasserjian, Sean M. Devlin, Heinz Tuechler, Juan Santiago Medina-Martinez, Tetsuichi Yoshizato, Yusuke Shiozawa, Ryunosuke Saiki, Luca Malcovati, Max Fine Levine, Juan E. Arango, Yangyu Zhou, Francesc Gessé Solé, Catherine A. Cargo, , Elli Papaemmanuil

The paper examines TP53 allelic states in MDS patients, finding that bi-allelic targeting is linked to worse outcomes, while mono-allelic targeting does not differ from wild-type patients.

Nature Medicine · Aug 3, 2020Peer-reviewedGenomics